Form 4: Turn Therapeutics Director Awarded 10,000 RSUs

Turn Therapeutics Director Arthur F. Golden was awarded 10,000 Restricted Stock Units under the company's 2025 Omnibus Incentive Plan, vesting based on service or change in control.

Summary

• Director Arthur F. Golden received an award of 10,000 Restricted Stock Units (RSUs) of Turn Therapeutics Inc. common stock.
• The RSUs were granted under the Issuer's 2025 Omnibus Incentive Plan.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest upon the earlier of the first anniversary of the grant date (October 8, 2026) or a change in control of Turn Therapeutics Inc.
• Vesting is subject to Mr. Golden's continuous service through the vesting date.
• The transaction date for this award was October 8, 2025.

Sentiment

Score: 7

Explanation: The award of Restricted Stock Units to a director is a positive signal for aligning management interests with shareholders, indicating commitment and incentivizing long-term performance. It's a standard compensation practice.

Positives

• The award of 10,000 Restricted Stock Units to Director Arthur F. Golden aligns his interests with long-term shareholder value.
• The vesting conditions, tied to continuous service and potential change in control, incentivize long-term commitment and performance from a key director.

Future Outlook

The Restricted Stock Units are set to vest upon the earlier of October 8, 2026, or a change in control of the Issuer, contingent on continuous service by Director Arthur F. Golden.

Industry Context

Restricted Stock Unit awards are a common form of equity compensation for directors and executives in publicly traded companies, particularly in sectors like biotechnology or pharmaceuticals, to align their long-term interests with those of shareholders.

Comparison to Industry Standards

• RSU awards are a standard component of director compensation packages across various industries, including life sciences. The specific size of the award (10,000 units) would typically be benchmarked against peer companies of similar market capitalization and stage of development, though such comparative data is not provided in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential long-term alignment of director interests with shareholder value. Future dilution from share issuance upon vesting.
• Management: Incentivizes Director Arthur F. Golden's continued service and performance.

Next Steps

• Continued service of Arthur F. Golden with Turn Therapeutics Inc.
• Vesting of the 10,000 Restricted Stock Units on October 8, 2026, or earlier upon a change in control.

Key Dates

Recommendation

This Form 4 reports a routine equity award to a director, which is a standard compensation practice designed to align management interests with shareholders. It does not contain information significant enough to alter an investment thesis or warrant a change in recommendation based solely on this filing.

Keywords

Turn Therapeutics, TTRX, Restricted Stock Units, RSU, Director Compensation, Equity Award, Incentive Plan, Form 4, Insider Transaction